High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not...
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42)...
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents...
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of...
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies,...
Powered by Infosys Topaz, the collaboration will help unify operations, optimize processes, and enable a future ready healthcare enterpriseBENGALURU, India...
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo”) is pleased to make known that its...